Fortress Biotech CEO granted 475,424 FBIO shares

ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.

Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.

Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.

Insider Trade Summary

Grant/Award: 475,424 shares

Grant/Award 1 txn

Insider ROSENWALD LINDSAY A MD

Role PRESIDENT, CEO & CHAIRMAN

Type	Security	Shares	Price	Value
Grant/Award	Common stock, par value $0.001	475,424	$0.00	$0.00

Holdings After Transaction: Common stock, par value $0.001 — 4,586,841 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fortress Biotech (FBIO) disclose for Lindsay Rosenwald?

Fortress Biotech disclosed that President, CEO & Chairman Lindsay A. Rosenwald received 475,424 restricted shares of common stock on March 18, 2026. The award was granted at no cash cost under the company’s Long-Term Incentive Plan as stock-based executive compensation.

How many Fortress Biotech (FBIO) shares does Lindsay Rosenwald hold after this Form 4?

After the March 18, 2026 grant, Lindsay A. Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. This figure includes the 475,424 restricted shares awarded under the Long-Term Incentive Plan as part of his equity-based compensation package.

Was the Fortress Biotech (FBIO) Form 4 an open-market stock purchase?

No, the Form 4 reports a grant of restricted shares, not an open-market purchase. Rosenwald received 475,424 common shares at a stated price of $0.00 per share under Fortress Biotech’s Long-Term Incentive Plan, reflecting compensation rather than a cash investment.

What plan governed the 475,424-share award in the Fortress Biotech (FBIO) Form 4?

The 475,424 restricted shares were granted pursuant to Fortress Biotech’s Long-Term Incentive Plan. The footnote specifies that the award was issued on March 18, 2026 as part of the company’s equity incentive program for executives, aligning pay with long-term shareholder interests.

What transaction code appears in Lindsay Rosenwald’s Fortress Biotech (FBIO) Form 4?

The transaction uses code “A,” which indicates a grant, award, or other acquisition. In this case, it represents the issuance of 475,424 restricted shares of Fortress Biotech common stock to Rosenwald under the company’s Long-Term Incentive Plan on March 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSENWALD LINDSAY A MD

(Last) (First) (Middle)

C/O FORTRESS BIOTECH, INC.

1111 KANE CONCOURSE SUITE 301

(Street)

BAY HARBOR ISLANDS FLORIDA 33154

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO & CHAIRMAN

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.001	03/18/2026		A		475,424(1)	A	$0	4,586,841	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted 475,424 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on March 18, 2026.

	/s/ Samuel Berry, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)